Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.60 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.44 |
| ▸ | GRK6 | P43250 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29008490 | 0.86 | CTSK (0.57) | HRH1HRH4SCN2APARP1CXCR2 | |
| SCHEMBL3023938 | 0.83 | CTSK (0.52) | HRH1HRH4SCN2ACXCR2PIN1 | |
| SCHEMBL31093434 | 0.83 | CTSK (0.52) | HRH1HRH4SCN2ACXCR2PIN1 | |
| SCHEMBL600053 | 0.83 | TAAR1 (0.50) | HRH1HRH4TAAR1PIN1GRK6 | |
| SCHEMBL2302422 | 0.79 | MAOB (0.55) | HRH1HRH4MAOBTAAR1XDH | |
| SCHEMBL15974857 | 0.79 | HRH1 (0.57) | HRH1HRH4TAAR1KDM4EMEN1 | |
| SCHEMBL3028276 | 0.79 | HRH1 (0.57) | HRH1MAOBTAAR1PARP1CXCR2 | |
| SCHEMBL1436268 | 0.78 | LOXL2 (0.40) | HRH1TAAR1CXCR2PIN1KDM4E | |
| SCHEMBL27642887 | 0.77 | SCN2A (0.51) | HRH1HRH4SCN2APARP1CXCR2 | |
| SCHEMBL15707366 | 0.76 | XDH (0.50) | HRH1HRH4MAOBSCN2APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673146-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | Biohaven Therapeutics Ltd. (VG) | 2026-01-07 | — | — | EP | claimed |
| WO-2024182465-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | ALCO THERAPEUTICS, LLC (US) | 2024-09-06 | — | — | WO | claimed |
| US-20100204205-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE AGENT BY USING THEM IN COMBINATION | OBECURE LTD. (IL) | 2010-08-12 | — | — | US | claimed |
| US-20100160294-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCES, INC. | 2010-06-24 | — | — | US | claimed |
| EP-2167096-A1 | IMPROVING THE TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | Cypress Bioscience, Inc. (US) | 2010-03-31 | — | — | EP | claimed |
| US-20090275562-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCES, INC. (US) | 2009-11-05 | — | — | US | claimed |
| WO-2008157094-A1 | IMPROVING THE TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCE, INC. (US) | 2008-12-24 | — | — | WO | claimed |
| EP-4673146-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | Biohaven Therapeutics Ltd. (VG) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024182465-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | ALCO THERAPEUTICS, LLC (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20100204205-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE AGENT BY USING THEM IN COMBINATION | OBECURE LTD. (IL) | 2010-08-12 | — | — | US | disclosed |
| US-20100160294-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCES, INC. | 2010-06-24 | — | — | US | disclosed |
| EP-2167096-A1 | IMPROVING THE TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | Cypress Bioscience, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090275562-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCES, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2008157094-A1 | IMPROVING THE TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCE, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| EP-1885708-A2 | GPCR MODULATORS | Board of Trustees of Michigan State University (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1877093-A2 | ASCORBATE BINDING PEPTIDES | Board of Trustees of Michigan State University (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1874356-A2 | AMINERGIC PHARMACEUTICAL COMPOSITIONS AND METHODS | Board of Trustees of Michigan State University (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006113557-A2 | GPCR MODULATORS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006113602-A2 | ASCORBATE BINDING PEPTIDES | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006113485-A2 | AMINERGIC PHARMACEUTICAL COMPOSITIONS AND METHODS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275562-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | HTR2A, HTR2C, HTR3A | HRH1 39/4885HRH4 28/4885MAOB 63/4885 |
| US-20100160294-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | HTR2A, HTR3A, HTR2C | HRH1 29/4885HRH4 23/4885MAOB 60/4885 |
| US-20100204205-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE AGENT BY USING THEM IN COMBINATION | HTR2A, HTR3A, HTR2C | HRH1 16/4885HRH4 17/4885MAOB 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.